BriaCell
1880 Century Park East, Suite #315
Los Angeles
California
90067
United States
Website: http://www.briacell.com/
85 articles about BriaCell
-
UPDATE - BriaCell Files Coronavirus Immunotherapy Patent
4/14/2020
BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining certain features thought to expand the clinical applications of BriaCell’s genetically engineered whole-cell immunotherapies to those of infectious diseases including the SARS-CoV-2 virus that causes Coronavirus Disease 2019.
-
BriaCell Files Coronavirus Immunotherapy Patent
4/14/2020
BriaCell Therapeutics Corp. announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining certain features thought to expand the clinical applications of BriaCell’s genetically engineered whole-cell immunotherapies to those of infectious diseases including the SARS-CoV-2 virus that causes Coronavirus Disease 2019.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
-
BriaCell to Present Clinical Data at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting May 29
3/31/2020
BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has been selected to present at the 2020 ASCO Annual Meeting, a virtual event held during the dates of the originally planned in-person Annual Meeting.
-
BriaCell Continues Clinical Operations Amidst COVID-19 Pandemic
3/26/2020
Phase I/IIa clinical study of BriaCell’s lead candidate, Bria-IMT™, with Incyte Corporation’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst the COVID-19 pandemic. Clinical and immune activity of Bria-IMT™, alone or in combination with checkpoint inhibitors, KEYTRUDA ® and INCMGA00012, in advanced breast cancer will be presented at the American Association for Cancer Research (AACR) Annual Meeting, postponed to August 2020. BERKELEY, Calif. and VA
-
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
-
BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade
1/9/2020
BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce it has identified a new group of patients with high levels of clinical benefit in response to its novel immunotherapy, and its combinations.
-
BriaCell Therapeutics Corp. Announces Share Consolidation
12/24/2019
BriaCell Therapeutics Corp. announces that its Board of Directors has approved a consolidation of the Company's issued and outstanding common shares on the basis of three hundred pre-consolidation shares for one post-consolidated share.
-
BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th
11/12/2019
BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce its lead product candidate, Bria-IMT™, will be featured in two poster sessions during the 2019 San Antonio Breast Cancer Symposium® taking place December 10-14 in San Antonio, Texas.
-
BriaCell Announces Voting Results of the Special Meeting of Shareholders
10/24/2019
BriaCell Therapeutics Corp. announced that the shareholders approved all matters addressed at the special meeting of the holders of common shares in the capital of BriaCell held on October 22, 2019.
-
Biotech Movers and Shakers for Aug. 13
8/13/2018
GSK's Hal Barron, former Juno Chief Executive Officer and others take on or transition into new roles. Let's take a look at some of those! -
BriaCell Adds New Clinical Site to Phase IIa Study in Advanced Breast Cancer and Expands R&D Team
8/8/2018
BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that the Cancer Center of Kansas (CCK) has been added as a new clinical trial site.
-
BriaCell Opens Fourth Clinical Site in Advanced Breast Cancer
2/6/2018
The company's CRO will manage the clinical and regulatory aspects of the clinical trial on behalf of BriaCell.
-
BriaCell Update: Early Evidence of Efficacy and Safety of Bria-IMT
1/31/2018
The company is pleased to provide a further update on its ongoing clinical trial of Bria-IM.
-
BriaCell Provides Clinical Update on its Lead Immunotherapy Drug in Advanced Breast Cancer
1/5/2018
BriaCell is providing a clinical update regarding its ongoing clinical trials of Bria-IMT.
-
BriaCell Announces Advancement of its Small Molecule Program and Patent Allowance
11/13/2017
The company disclosed the allowance by the USPTO and also the EPO of two patent applications related to protein kinase C delta (PKCδ) inhibitor technology,
-
BriaCell Provides Clinical Update on its Lead Vaccine Candidate, BriaVax
11/6/2017
The Phase I/IIa study evaluates the safety and activity of BriaVax in patients with advanced breast cancer. To boost the anti-tumor effects of BriaVax.
-
FDA Approves BriaCell's Roll-Over Combination Study with Checkpoint Inhibitor Immunotherapies to Allow Continued Access to BriaVax in Patients With Advanced Breast Cancer
10/30/2017
The study allows the patients who did not respond to BriaVax to be treated in combination with either pembrolizumab or ipilimumab.
-
BriaCell Adds Third Clinical Site – Led By Top Physician-Scientist Dr. Lukas – To Expand Phase I/IIa Clinical Trial In Advanced Breast Cancer
9/25/2017
-
BriaCell Provides Research Update
9/14/2017